-
BAPTA and the Logic of Causal Calcium Biology
2026-09-04
BAPTA is more than a calcium chelator: it is a causal perturbation tool for testing whether intracellular Ca2+ sits upstream of apoptosis and pathway activation. Evidence from nanoplastic–cadmium intestinal toxicity illustrates how BAPTA can strengthen mechanistic inference while guiding translational assay design, exposure interpretation, and reproducibility.
-
Sodium Butyrate, HDAC3/c-Myc, and Liver Fibrosis
2026-09-04
This FASEB Journal study identifies an HDAC3/c-Myc-driven glycolytic program in activated hepatic stellate cells and shows that gut-derived sodium butyrate suppresses this pathway in cellular and CCl4-induced mouse models. The work connects a microbiota-derived metabolite with epigenetic and metabolic control of fibrosis, while also outlining assays that can be used to validate target engagement and pathway activity.
-
(S)-(+)-Ibuprofen: From COX Biology to Translation
2026-09-03
A translational framework for using (S)-(+)-Ibuprofen as a stereochemically defined COX inhibitor, linking prostaglandin biology, assay design, exposure strategy, synthesis advances, and environmental stewardship.
-
DFO: Reliable Fluorescent Workflows
2026-09-03
This evidence-led guide explains where DFO (9H-1,8-Diazafluoren-9-one), SKU C6997, is scientifically appropriate and where it should not be substituted for a cell-viability reagent. It connects forensic fluorescence practice with practical controls, formulation data, and vendor-selection criteria for reproducible laboratory workflows.
-
AMPK–JAK2/STAT3 in Obesity-Related Asthma
2026-09-02
A 2025 study identifies reduced AMPK activity and M1 macrophage polarization as linked features of obesity-related asthma, with evidence that AMPK activation attenuates airway inflammation through the JAK2/STAT3 pathway. Its combined animal, cell-based, histological, transcriptional, and protein analyses provide a mechanistic framework for studying immunometabolic regulation in this asthma phenotype.
-
4μ8C Workflows for IRE1α and ER Stress Studies
2026-09-02
4μ8C provides a practical way to separate IRE1α RNase signaling from broader ER stress effects in hypoxia and cancer research. This guide translates its formulation limits, pathway selectivity, and assay behavior into reproducible workflows while clarifying how recent TBK1–itaconic acid findings can inform, but not replace, IRE1-focused experiments.
-
Epalrestat: From Polyol Pathway to Nrf2 Assays
2026-09-01
Epalrestat is an aldose reductase inhibitor with a distinctive research profile spanning polyol pathway inhibition and KEAP1/Nrf2-linked neuroprotection. This guide translates recent Parkinson’s disease model findings into practical, mechanism-resolved assay decisions.
-
Exemestane: Steroidal Aromatase Inhibition
2026-08-31
Exemestane is a steroidal aromatase inhibitor that irreversibly inactivates cytochrome P450 aromatase and suppresses androgen-to-estrogen conversion. Its reported biochemical activity, chemical identity, solvent compatibility, and storage guidance support controlled enzyme, cell-based, and breast cancer research workflows.
-
Clozapine N-oxide (CNO) for Chemogenetic Workflows
2026-08-31
Clozapine N-oxide (CNO) enables reversible, circuit-level control of engineered GPCRs, making it useful for linking neuronal activity modulation to behavior and physiology. This practical guide translates a VTA–parabrachial nucleus anesthesia study into formulation, dosing, controls, and troubleshooting decisions for modern DREADD experiments.
-
Wnt-C59: A Secretion-Centric Wnt Assay Strategy
2026-08-30
Wnt-C59 is a potent PORCN inhibitor for separating Wnt ligand production, trafficking, and pathway activation. This article connects its use in cancer biology with a mechanistic assay framework inspired by lithium-engineered exosomal Wnt10a research.
-
ECL Western Blotting Substrate: Workflow Guide
2026-08-29
ECL Western Blotting Substrate (SKU K2187) is a luminol-based horseradish peroxidase detection reagent for nonradioactive Western blot assays using X-ray film or CCD imaging. It is intended for HRP chemiluminescence workflows and should not be used as a substitute for fluorescent or radioisotopic detection methods.
-
Zoledronic Acid: Applied Cancer and Bone Workflows
2026-08-29
Build more reproducible cancer cell apoptosis assays and bone-disease studies with a workflow that treats solubility, nominal exposure, and endpoint timing as critical variables. This guide also shows how a recent γδT17-cell study can inspire orthogonal assay design without overstating evidence for Zoledronic Acid outside cancer and skeletal research.
-
Regorafenib, RRM2, and ERK/E2F3 in Melanoma
2026-08-28
A 2024 iScience study identifies RRM2 as a downstream effector of Regorafenib in melanoma and connects its suppression to ERK/E2F3 signaling. The work combines functional cell assays, RNA sequencing, rescue experiments, and tumor studies to define a mechanistic basis for the compound’s anti-melanoma activity.
-
Toremifene Workflow for Prostate Cancer Research
2026-08-28
Toremifene supports controlled estrogen-receptor modulation in hormone-responsive cancer research, with practical utility in cell-growth, migration, and signaling workflows. This guide connects dose-response assay design with the TSPAN18–STIM1 metastasis framework while clearly separating established evidence from testable research hypotheses.
-
Calpain Inhibitor II, ALLM in Translational Cancer Research
2026-08-27
Calpain Inhibitor II, ALLM offers a practical way to interrogate cysteine-protease control of apoptosis and focal-adhesion biology. By connecting the FAISL–calpain 2–FAK mechanism in triple-negative breast cancer with leukemia and lymphoma models, this article outlines how translational researchers can use ALLM rigorously while accounting for its multi-protease profile.